Clinical and Economic Burden of Pneumococcal Disease Among Adults in Sweden: A Population-Based Register Study

Author(s)

Zarabi N1, Aldvén M2, Sjölander S1, Fues Wahl H2, Bencina G3, Johnson KD4, Silfverdal SA5
1MSD Sweden, Stockholm, Sweden, 2Quantify Research, Stockholm, Sweden, 3MSD, Center for Observational and Real World Evidence (CORE), Madrid, Spain, 4Center for Observational and Real-World Evidence, Merck & Co., Inc., Rahway, NJ, USA, 5Umeå University, Umeå, Sweden

Presentation Documents

OBJECTIVES:

Pneumococcal disease (PD) is a major cause of morbidity, mortality, and economic burden worldwide. This study investigated the clinical and economic burden of PD in adults aged ≥65 years in Sweden.

METHODS: A retrospective population-based study was conducted using Swedish national registers, including patients aged 65-74 and ≥75 years with a diagnosis of pneumococcal pneumonia, meningitis and septicaemia in inpatient or outpatient specialist (hospital) care between 2015-2019. Incident PD infections were defined as diagnoses occurring >30 days apart. PD incidence, 30-day all-cause case fatality rate (CFR), healthcare resource utilisation and costs were estimated, and stratified on clinical presentation.

RESULTS:

During the study period, 6,717 incident infections were identified among 6,334 adults (65-74y: 42.1%, ≥75y: 57.9%). Medical risk factors (RF) associated with higher risk for severe disease were present in 57% (65-74y: 55%, ≥75y: 58%) of patients. PD incidence was estimated at 52.10 (64-74y) and 85.32 (≥75y) per 100,000 population, corresponding to 2,888 (64-74y) and 3,829 (≥75y) incident infections, of which 92.6% and 96.9% respectively required hospitalisation. The 30-day average number of hospitalisations was 1.24 (64-74y) and 1.31 (≥75y), with mean length of stay (LOS) of 7.77 (65-74y) and 8.78 (≥75y) days. Longest LOS was observed among meningitis patients (65-74y: 12.10, ≥75y: 12.89). The average 30-day cost/infection was estimated to €5,300 (65-74y) and €5,900 (≥75y). The 30-day total direct cost of PD between 2015-2019 was €15.2/€22.6 million (65-74y/≥75y) (pneumonia: 76.6%/81.6%, meningitis: 8.7%/3.4%, septicaemia: 14.7%/14.9%). The 30-day CFR (65-74y: 5.4%, ≥75y: 11.7%) increased with age, and was highest among septicemia patients ≥75y (21.4%).

CONCLUSIONS:

Both clinical and economic burden of PD was found to be high and generally comparable between age groups, but PD incidence and CFR was higher among the ≥75 year old. Infections were common among individuals with no recorded RF’s and costs were largely driven by hospitalisation.

Conference/Value in Health Info

2022-11, ISPOR Europe 2022, Vienna, Austria

Value in Health, Volume 25, Issue 12S (December 2022)

Code

EPH120

Topic

Economic Evaluation, Epidemiology & Public Health, Study Approaches

Topic Subcategory

Registries

Disease

No Additional Disease & Conditions/Specialized Treatment Areas

Explore Related HEOR by Topic


Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×